Its high accumulation at tumor sites and effective binding with PD-L1 on tumor cells eventually block the PD1/PD-L1 inhibitory axis by exhausting PD-L1 on tumor cells, leading to a higher antitumor response. The gene discussed is CD274; the disease is neoplasm.